

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **The United Laboratories International Holdings Limited**

**聯邦制藥國際控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

(Stock Code: 3933)

### **UPDATED INFORMATION ON THE GROUP'S PRODUCT LIRAGLUTIDE INJECTION**

This announcement is made by The United Laboratories International Holdings Limited (the "Company") on a voluntary basis.

The board of directors (the "Board") of the Company is pleased to announce that the Liraglutide Injection (specification: 3ml:18mg (prefilled)) submitted by Zhuhai United Bio-Pharmaceutical Co., Ltd, a wholly-owned subsidiary of the Company, has been approved by China National Medical Products Administration ("NMPA"), with reference number of S20250014.

Liraglutide Injection, a recombinant human glucagon-like peptide-1 (GLP-1) analog, is indicated for blood glucose control in adult patients with type 2 diabetes; and for use in combination with metformin or sulfonylurea medications in patients whose blood glucose remains inadequately controlled despite the maximum tolerated dose of metformin or sulfonylurea alone. It can meet the hypoglycemic needs of patients at the dosage of one injection per day.

In December 2024, Zhuhai United Bio-Pharmaceutical Co., Ltd, along with its Liraglutide Injection, Insulin Degludec Injection and Semaglutide Injection was approved by NMPA to become the first batch of biopharmaceutical enterprises authorized for segmented production and pilot varieties in Guangdong Province. By implementing an innovative production model, the Company enhances manufacturing efficiency and product quality, ensuring a stable market supply while benefiting a broad patient population.

Focusing on the GLP-1 target, the Company has developed a differentiated product pipeline that integrates both innovative drugs and biosimilars, which helps enhance the Company's market competitiveness in the biopharmaceutical field. In the future, the Company will continue to commit itself to new product research and development, with a view of creating more benefits for the Company and its shareholders.

By Order of the Board  
**The United Laboratories International Holdings Limited**  
**Tsoi Hoi Shan**  
*Chairman*

Hong Kong, 21 March 2025

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Dr. Fu Qiushi as independent non-executive directors.